Stock Events

Stock Events

Cellectar Biosciences 

$1.2050
60
-$0.01-1.23%Friday 20:00
+$0.04+3.73%Friday 23:35After hours

Statistics

Day High
1.205
Day Low
1.205
52W High
4.7
52W Low
1.12
Volume
329
Avg. Volume
-
Mkt Cap
11.39M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 2Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-4.9
-3.29
-1.68
-0.07
Expected EPS
-0.5565
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-21.79MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is ⁦10.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLRB. It's not an investment recommendation.
Tesla
9
TSLA
Apple
8
AAPL
Amazon
7
AMZN
NVIDIA
6
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Adc Therapeutics SA
ADCT
Mkt Cap144.26M
ADC Therapeutics focuses on developing antibody-drug conjugates for cancer treatment, directly competing with Cellectar's cancer-targeting therapies.
Allogene Therapeutics
ALLO
Mkt Cap518.24M
Allogene Therapeutics works on allogeneic CAR T cell therapies, a different but competing approach in the broader cancer treatment landscape against Cellectar's offerings.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the oncology space, particularly in cell therapies that could be alternatives to Cellectar's treatments.
Novartis
NVS
Mkt Cap268B
Novartis offers a broad range of oncology treatments, including targeted therapies and cell therapy products that compete with Cellectar's cancer treatments.
AMGEN
AMGN
Mkt Cap217.9B
Amgen's extensive portfolio in oncology, including biosimilars and novel therapeutics, positions it as a competitor across various aspects of cancer treatment, challenging Cellectar's market.

About

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Show More
CEO
James V. Caruso
Employees
11
Country
United States
ISIN
US15117F8804
WKN
000A41BQ3

Listings

STU
DE
NV40.STU
MU
DE
NV4P.MU
MU
DE
NV40.MU
XNAS
US
CLRB

0 Comments

Share your thoughts

FAQs

What is Cellectar Biosciences stock price today?▼
The current price of CLRB is $1.21 USD — it has decreased by -1.23% in the past 24 hours. Watch Cellectar Biosciences stock price performance more closely on the chart.
What is Cellectar Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cellectar Biosciences stocks are traded under the ticker CLRB.
Is Cellectar Biosciences stock price growing?▼
CLRB stock has fallen by -1.23% compared to the previous week, the month change is a -35.56% fall, over the last year Cellectar Biosciences has showed a -64.45% decrease.
What is Cellectar Biosciences market cap?▼
Today Cellectar Biosciences has the market capitalization of 11.39M
When is the next Cellectar Biosciences earnings date?▼
Cellectar Biosciences is going to release the next earnings report on November 2, 2026.
What were Cellectar Biosciences earnings last quarter?▼
CLRB earnings for the last quarter are -0.57 USD per share, whereas the estimation was -0.52 USD resulting in a -9.62% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cellectar Biosciences revenue for the last year?▼
Cellectar Biosciences revenue for the last year amounts to 0 USD.
What is Cellectar Biosciences net income for the last year?▼
CLRB net income for the last year is -21.79M USD.
How many employees does Cellectar Biosciences have?▼
As of November 1, 2026, the company has 11 employees.
In which sector is Cellectar Biosciences located?▼
Cellectar Biosciences operates in the Health & Wellness sector.
When did Cellectar Biosciences complete a stock split?▼
The last stock split for Cellectar Biosciences was on June 24, 2025 with a ratio of 1:30.
Where is Cellectar Biosciences headquartered?▼
Cellectar Biosciences is headquartered in FLORHAM PARK, United States.